Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

被引：1

作者：

Yang, Li ^{[1
]}

Chen, Fangli ^{[1
]}

Liang, Hong ^{[2
]}

Bai, Yunsong ^{[3
]}

Wu, Wenzhong ^{[4
]}

Yan, Xiaojing ^{[5
]}

Ren, Jinhai ^{[6
]}

Li, Si ^{[2
]}

Yu, Yang ^{[2
]}

Tong, Laigen ^{[4
]}

Pan, Deng ^{[5
]}

Liu, Ligen ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Hematol,Hongqiao Int Inst Med, Shanghai, Peoples R China

[2] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China

[3] Jilin Univ, China Japan Union Hosp, Dept Hematol, Changchun, Peoples R China

[4] Yixing Peoples Hosp, Yixing, Peoples R China

[5] China Med Univ, Hosp 1, Shenyang, Peoples R China

[6] Hebei Med Univ, Hosp 2, Dept Hematol, Shijiazhuang, Hebei, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184581

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
DiNardo, Courtney D.
Stein, Anthony S.
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Doehner, Hartmut
Martinelli, Giovanni
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Lam, Du
Wang, Xiwei
Gong, Jing
Kapsalis, Stephanie M.
Hickman, Denice
Zhang, Vickie
Winkler, Thomas
Daigle, Scott
Vyas, Paresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
[42] How to Improve the Efficacy of Venetoclax and Azacitidine(VA)for Newly Diagnosed Acute Myeloid Leukemia?a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
Li, Xuekai
Li, Mengyun
Cui, Wei
Chen, Xiaoqian
Yu, Yan
Chen, Juan
Zhang, Xin
Cui, Qingya
Wu, Depei
Tang, Xiaowen
BLOOD, 2024, 144 : 4284 - 4284
[43] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
Ong, Faustine
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Ohanian, Maro
Konopleva, Marina
Jabbour, Elias
Jain, Nitin
Borthakur, Gautam
DiNardo, Courtney D.
Daver, Naval
Issa, Ghayas C.
Sasaki, Koji
Chien, Kelly S.
Takahashi, Koichi
Andreeff, Michael
Muftuoglu, Muharrem
Delumpa, Ricardo
Mayor, Ejiroghene
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Kantarjian, Hagop
Cortes, Jorge E.
Short, Nicholas
BLOOD, 2022, 140 : 6206 - 6208
[44] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
Xu, Xuezhu
Liu, Rui
Chen, Hongli
Yang, Ruoyu
Gao, Gongzhizi
He, Aili
Wang, Fangxia
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
[45] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
Doyel, Michael
Bouligny, Ian Michael
Murray, Graeme
Patel, Tilak
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Thuy Ho
Zacholski, Kyle
Venn, Chad Michael
Alnimer, Yanal Mufeed
Wages, Nolan
Grant, Steven
Maher, Keri Renee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study
Zhang, Jian
Song, Baoquan
Liu, Yin
Wu, De-Pei
Qiu, Huiying
BLOOD, 2023, 142
[47] A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
Garcia-Manero, Guillermo
Fong, Chun Yew
Venditti, Adriano
Mappa, Silvia
Spezia, Riccardo
Ades, Lionel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
Mims, Alice
Xie, Zhuoer
Potluri, Ravi
Rotter, David
Chevli, Manoj
Prebet, Thomas
Gaugler, Lona
Strocchia, Maria
Vasconcelos, Alberto
Sieluk, Jan
LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 479 - 487
[49] Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry
Labrador, Jorge
Martinez-Cuadron, David
de la Fuente, Adolfo
Rodriguez-Veiga, Rebeca
Serrano, Josefina
Tormo, Mar
Perez-Simon, Jose Antonio
Ramos, Fernando
del Castillo, Teresa Bernal
Lopez-Pavia, Maria
Trigo, Fernanda
Sanchez, Pilar Martinez
Rodriguez-Gutierrez, Juan Ignacio
Rodriguez, Carlos
Gil, Cristina
Garcia, Daniel
Vives, Susana
Foncillas, Maria Angeles
Encinas, Manuel Perez
Novo, Andres
Recio, Isabel
Rodriguez-Macias, Gabriela
Burgues, Juan Miguel Bergua
Concepcion, Victor Noriega
Lavilla, Esperanza
Perez, Alicia Roldan
Sanz, Miguel A.
Montesinos, Pau
BLOOD, 2020, 136
[50] Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador, Jorge
Martinez-Cuadron, David
de la Fuente, Adolfo
Rodriguez-Veiga, Rebeca
Serrano, Josefina
Tormo, Mar
Rodriguez-Arboli, Eduardo
Ramos, Fernando
Bernal, Teresa
Lopez-Pavia, Maria
Trigo, Fernanda
Martinez-Sanchez, Maria Pilar
Rodriguez-Gutierrez, Juan-Ignacio
Rodriguez-Medina, Carlos
Gil, Cristina
Belmonte, Daniel Garcia
Vives, Susana
Foncillas, Maria-Angeles
Perez-Encinas, Manuel
Novo, Andres
Recio, Isabel
Rodriguez-Macias, Gabriela
Bergua, Juan Miguel
Noriega, Victor
Lavilla, Esperanza
Roldan-Perez, Alicia
Sanz, Miguel A.
Montesinos, Pau
CANCERS, 2022, 14 (09)

← 1 2 3 4 5 →